Analysis of Outpatient HER2 Testing in New York State Using the Statewide Planning and Research Cooperative System
Background: Human epidermal growth factor-2 (HER2) testing is necessary in the context of therapy with trastuzumab, pertuzumab, lapatinib, and neratinib. There is a paucity of reports describing the utilization rates of HER2 testing in large outpatient populations.
Methods: The Statewide Planning and Research Cooperative System (SPARCS) was used to examine HER2 testing across the state of New York during the 2012-2016 period.
Results: There was a linear increase in HER2 testing (r = 0.91, p = 0.030). There were increases in HER2 testing observed among minorities, including a 0.5-fold and 3.5-fold increases in individuals identified as black and Asian, respectively. Major state population centers showed the highest HER2 testing.
Conclusions: This study establishes a platform to further evaluate clinical utility, outcomes, and equity of access for “precision oncology” testing.